Infinitus (China) Company Ltd., a member of LKK Health Products Group (LKKHPG), officially kicked off the Chinese Herbal Medicine Research and Safety Assessment Centre (“the Centre”) in Guangzhou on 15 July 2016. The Centre is designed to take advantage of modern science to conduct research on quality standards, safety, measurement technologies, processing techniques, application theories, as well as the mechanism that controls the effectiveness of Chinese herbal medicine. In addition, the Centre will provide professional support in terms of science-based technologies and safety assessment in a move to boost the orderly, scientific and healthy development of the Chinese herbal medicine industry.
Global demand for natural medicine has been rising for years, helping a variety of products with Chinese herbal medicines as active ingredients rise in popularity globally. Despite being a traditional leader in Chinese herbal medicine, China is relatively weak when it comes to safety control. Safety assessment is one of the hot topics when it comes to discussing challenges facing modern research into Chinese herbal medicine.
Mr. Tim Chun, Senior Vice President of LKKHPG said: "In-depth research into Chinese herbal medicine and product safety will not only boost safety applications, but also help Chinese players stay current with international research technologies, serving to enhance China's competitiveness in the global Chinese herbal medicine market."
The Centre is committed to becoming a renowned research platform as well as an independent and professional safety assessment center for Chinese herbal medicine. With an initial investment of RMB 43 million, the Centre comes equipped with advanced scientific measuring tools and instruments in accordance with standards of China's key national labs as well as professional physical, chemical and precision lab instruments specifically tailored for Chinese herbal medicine. In addition, the Centre will join hands with leading domestic and foreign research institutions and teams in building a multidisciplinary and participatory research platform. To date, the Centre has received support from a number of institutions and universities including the Guangdong Institute of Microbiology, the University of Macau, the Guangzhou University of Chinese Medicine, the South China University of Technology, the South China Agricultural University as well as other national key laboratories.
The Joint Research Centre for Safety and function of Edible-Medicinal Fungi ("Fungi Centre"), launched on the same day, was set up jointly by Infinitus (China) and the Guangdong Institute of Microbiology, an organization with a long list of achievements in the research of edible and medicinal fungi. The Fungi Centre is the Center's first platform built and shared with an external organization. The Fungi Centre will focus on research into the medical properties of edible and medicinal fungi and how they interact with the human body as well as how these findings can be applied to further technological development, biological risk assessment across the industry chain as well as prevention and control technologies. In the future, the Centre will build additional specialized Chinese herbal research platforms with an eye to innovation and collaborative inclusiveness.
In addition, the Centre plans to provide the entire industry and the larger Traditional Chinese Medicine community with technical support and safety assessment services. In the future, the Centre plans to address demand from consumers for evaluation in the safety and effectiveness of Chinese herbal products by providing them with third-party testing services related to Chinese herbal medicine.
With over two decades of experience in research into and development of Chinese herbal health products, Infinitus has invested over RMB100 million (approx. US$15 million) in product development each year. With the support of China's largest team engaged in development of Chinese herbal health products, the company has proprietary technology on Herbal Polysaccharides, Schizandrin B, Compound Whitening Factor, Bioactive Peptide and many others. Infinitus has now expanded its presence in the Chinese mainland, Hong Kong, Taiwan and Malaysia.
Mr. Harry Yeung, Senior Vice President of LKKHPG, said, "The launch of the Centre will support the Group's new product development and product testing services, as well as boost the standardization and modernization of the Chinese herbal medicine industry worldwide, serving to benefit more consumers."